A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Clinical trial NCT06880354 · RECRUITING
Trial details
- NCT number
- NCT06880354
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
- Status
- RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2025-05-22
- Primary completion
- 2028-03-31
- Enrollment
- 37
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.